These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22320027)

  • 1. Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine.
    Vosburg SK; Sullivan MA; Comer SD
    J Opioid Manag; 2011; 7(6):451-61. PubMed ID: 22320027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
    Shaibani AI; Pope LE; Thisted R; Hepner A
    Pain Med; 2012 Feb; 13(2):243-54. PubMed ID: 22314263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers.
    Comer SD; Sullivan MA
    Psychopharmacology (Berl); 2007 Aug; 193(2):235-45. PubMed ID: 17406858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine withdrawal-emergent catatonia.
    Turner J; Mitchell JL; Carroll BT; Denysenko L
    Ann Clin Psychiatry; 2016 May; 28(2):138-9. PubMed ID: 26855991
    [No Abstract]   [Full Text] [Related]  

  • 5. Dextromethorphan and quinidine combination for heroin detoxification.
    Akerele E; Bisaga A; Sullivan MA; Garawi F; Comer SD; Thomas AA; Nunes EV; Kleber HD
    Am J Addict; 2008; 17(3):176-80. PubMed ID: 18463993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.
    Pope LE; Schoedel KA; Bartlett C; Sellers EM
    Clin Drug Investig; 2012 Aug; 32(8):e1-15. PubMed ID: 22712629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Dextromethorphan/Quinidine for Patients With Psychosis-Related Aggression: A Retrospective Case Series.
    Chen Q; Calcagno HE; Shad M
    Prim Care Companion CNS Disord; 2018 Jun; 20(3):. PubMed ID: 29985567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
    Carbonaro TM; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
    Comer SD; Collins ED
    J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.
    Kelly TF; Lieberman DZ
    J Affect Disord; 2014; 167():333-5. PubMed ID: 25016490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous buprenorphine self-administration by detoxified heroin abusers.
    Comer SD; Collins ED; Fischman MW
    J Pharmacol Exp Ther; 2002 Apr; 301(1):266-76. PubMed ID: 11907183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.
    Stahl SM
    CNS Spectr; 2013 Oct; 18(5):225-7. PubMed ID: 24050154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.
    Sullivan MA; Vosburg SK; Comer SD
    Psychopharmacology (Berl); 2006 Nov; 189(1):37-46. PubMed ID: 16972105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment.
    Lee SY; Chen SL; Chang YH; Chu CH; Chen SH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
    Int J Neuropsychopharmacol; 2015 Feb; 18(7):pyv008. PubMed ID: 25716777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.
    Comer SD; Sullivan MA; Walker EA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1320-30. PubMed ID: 16144974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
    Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
    Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
    Schoedel KA; Pope LE; Sellers EM
    Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
    Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
    Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.